CVS Caremark Corp.'s CVS -0.29%fourth-quarter net profit rose 2.6% as the company reported revenue growth in its pharmacy-services and retail drugstore operations.
For the year, the company raised its forecast for per-share adjusted earnings from continuing operations by two cents and now expects $3.86 to $4.
Track the performances of 150 companies as they report and compare their results with analysts' estimates. Sort by date and industry.
More photos and interactive graphics
CVS's retail pharmacy business gained customers last year in the wake of a contract dispute between rival Walgreen Co.'s WAG -0.16%and pharmacy-benefits manager Express Scripts Holding Co. ESRX -0.93%that has since been resolved.
A wave of major generic drugs introductions is having a mixed effect on the industry. Though the copycat drugs carry higher margins than branded products, they command lower prices, hurting sales revenue.
CVS Caremark reported a profit of $1.13 billion, or 90 cents a share, up from $1.1 billion, or 81 cents a share, a year earlier. Excluding debt-extinguishment losses, acquisition-related charges and other items, adjusted earnings from continuing operations were $1.14. Revenue increased 11% to $31.39 billion.
Analysts polled by Thomson Reuters most recently projected earnings of $1.10 on revenue of $31.13 billion.
Revenue in the larger pharmacy-services business climbed 17% to $18.6 billion, reflecting new client starts, higher prices and growth of its Medicare Part D program. Pharmacy network claims processed rose 6.5%.
On the retail side, revenue increased 5.1% to $16.3 billion. Same-store sales were up 4% from a year earlier, as pharmacy same-store sales also improved by 4%. Same-store sales in the front end of the store grew 3.9%.